Methotrexate+Medical Ozone combined therapy in Rheumatoid Arthritis. From experimental models to clinical trials [abstract]
DOI:
https://doi.org/10.7203/jo3t.3.4.2019.15515Keywords:
ozone therapy, rheumathoid arthitisAbstract
INTRODUCTION: The aim of this work has been to investigate the medical ozone effects on 2 experimental models: PG/PS induced RA and synovitis followed for a clinical trial of efficacy. METHODS: mRNA levels of TNF-alpha and IL-1 beta, injury and protective biomarker of oxidative stress, morphology studies, A1 adenosine receptor role, Anti-Cyclic Citrullinated (Anti-CCP) levels and clinical variables were determined. RESULTS: Medical ozone ameliorated the expression of proinflammatory cytoquines, reduced oxidative damage while participation of A1 adenosine receptor in the antiinflammatory effects was demonstrated. In RA patients (n=60) MTX + ozone reduced the activity of the disease while MTX merely showed a tendency to decrease it. MTX + ozone reduced Anti-CCP levels as well as increased antioxidant system, and decreased oxidative damage whereas MTX did not change. CONCLUSIONS: Medical ozone was effective in the reduction of inflammatory response in 2 experimental studies. MTX + ozone increased the MTX clinical efficacy in RA patients. These results suggest that ozone can increase the efficacy of MTX probably because both share common therapeutic targets.Downloads
Downloads
Published
How to Cite
-
Abstract576
-
PDF314
Issue
Section
License
Journal of Ozone Therapy applies the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY NC 4.0) license to works we publish.
Under this license, authors retain ownership of the copyright for their content, but allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. No permission is required from the authors or the publishers.
You may not use the material for commercial purposes.
Appropriate attribution can be provided by simply citing the original article, provide a link to the license, and indicate if changes were made.
You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.